

The Republic of Tajikistan

Support for Vaccine: Inactivated Polio Virus This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	The Republic of Tajikistan																						
2. Vaccine grant number:	15-TJK-08h-Y, 1518-TJK-25b-X, 18-TJK-08p-Y, 19-TJK-25b-X, 20-TJK-25b-X																						
3. Date of Decision Letter:	30 September 2019																						
4. Date of the Partnership Framework Agreement:	07 November 2012																						
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine																						
6. Vaccine type:	Inactivated Polio Virus																						
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 5 doses per vial, LIQUID																						
8. Programme Duration:¹	2015-2020																						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)																						
	2015-2019	2020	Total ²																				
Programme Budget (US\$)	1,430,864	1,001,000	2,431,864																				
10. Vaccine introduction grant	Not applicable																						
	<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="text-align: center;">Year</th> <th style="text-align: center;">Grant Number</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2015</td> <td style="text-align: center;">15-TJK-08h-Y</td> <td style="text-align: center;">222,000</td> </tr> <tr> <td style="text-align: center;">2018</td> <td style="text-align: center;">18-TJK-08p-Y</td> <td style="text-align: center;">126,817</td> </tr> </tbody> </table> <table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="text-align: center;">Disbursement date</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">01 October, 2014</td> <td style="text-align: center;">222,000</td> </tr> <tr> <td style="text-align: center;">17 July, 2018</td> <td style="text-align: center;">126,817</td> </tr> </tbody> </table>			Approval			Year	Grant Number	Amount (US\$)	2015	15-TJK-08h-Y	222,000	2018	18-TJK-08p-Y	126,817	Disbursement		Disbursement date	Amount (US\$)	01 October, 2014	222,000	17 July, 2018	126,817
Approval																							
Year	Grant Number	Amount (US\$)																					
2015	15-TJK-08h-Y	222,000																					
2018	18-TJK-08p-Y	126,817																					
Disbursement																							
Disbursement date	Amount (US\$)																						
01 October, 2014	222,000																						
17 July, 2018	126,817																						
11. Product switch grant	Not applicable																						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)																						
	2015-2019	2020																					
Type of supplies to be purchased with Gavi funds																							
Number of vaccine doses		368,700																					
Annual Amounts (US\$)	1,430,864	1,001,000																					

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement:	Not applicable						
15. Co-financing obligations:	Not applicable						
16. Operational support for campaigns:	Not applicable						
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	To prepare for the annual procurement of vaccines, Country shall submit the <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed 	31 March 2020 15 May 2020						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat						
18. Financial clarifications:	No applicable						
19. Other conditions:	<p>Not applicable</p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>						

Signed by,

Signed by,

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

September 30, 2019